[Editorial] Back to Basics in Sickle Cell Disease

Why It Matters

Without equitable access to basic treatments and early detection, sickle cell disease will continue to cause preventable deaths and strain health systems, especially in low‑resource settings.

Key Takeaways

• 8 million people live with sickle cell disease globally.
• Deaths rose 18.4% from 2000‑2023.
• Curative gene therapies cost $2‑3 million, inaccessible to most.
• Hydroxyurea, penicillin, transfusion remain underused worldwide.
• Newborn screening pilots reached 160 k infants in Africa.

Pulse Analysis

Sickle cell disease remains one of the fastest‑growing genetic disorders, with the Global Burden of Disease study estimating nearly eight million affected individuals. Mortality has risen sharply, driven by limited diagnostic capacity and fragmented care, especially in sub‑Saharan Africa where most newborns with the disease die before age five. High‑income nations also grapple with shortened life expectancy due to multi‑organ complications, underscoring that the disease’s impact transcends geographic and economic boundaries.

The therapeutic landscape is a study in contrast. Gene‑editing approaches such as exagamglogene autotemcel promise cures but carry price tags of $2‑3 million per dose, restricting administration to fewer than 50 patients in the UK and none in low‑income regions. Recent withdrawals of voxelotor and crizanlizumab further narrow options, while proven, inexpensive interventions—hydroxyurea, penicillin prophylaxis, and safe blood transfusion—remain under‑utilised due to supply shortages and data gaps. Accurate epidemiological data are essential for allocating resources and designing effective programs, yet many regions lack reliable registries.

Policy makers and global health partners are now focusing on scalable, evidence‑based solutions. Initiatives like the SickleInAfrica consortium and the American Society of Hematology’s newborn‑screening program have collectively screened over 160,000 infants, aiming for universal coverage by 2025. Integrating a core care package into primary health services, bolstering electronic patient registries, and securing funding for essential medicines could dramatically lower morbidity and mortality. Prioritising these basic measures offers a pragmatic path to equity while the high‑cost curative therapies continue to evolve.